YAP1 promotes high glucose‑induced inflammation and extracellular matrix deposition in glomerular mesangial cells by modulating NF‑κB/JMJD3 pathway

Wang,Yan; Xu,Jinmei; Cheng,Zhifeng

doi:10.3892/etm.2021.10784

YAP1 promotes high glucose‑induced inflammation and extracellular matrix deposition in glomerular mesangial cells by modulating NF‑κB/JMJD3 pathway

Authors:
- Yan Wang
- Jinmei Xu
- Zhifeng Cheng
View Affiliations

Affiliations: Department of Endocrinology, Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China
Published online on: September 23, 2021 https://doi.org/10.3892/etm.2021.10784
Article Number: 1349
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Diabetic nephropathy (DN) is one of the most serious microvascular complications of late‑stage diabetes. Glomerular mesangial cell (GMC) proliferation and excessive extracellular matrix (ECM) deposition are the main pathological characteristics associated with the occurrence and development of DN. Yes‑associated protein 1 (YAP1) can bind to several transcription factors and is associated with the development of various diseases. However, the effects of YAP1 on DN remain unclear. The aim of the present study was to explore the regulatory effect and potential mechanism of YAP1 in glucose‑induced inflammation and ECM deposition in high‑glucose‑treated GMCs. In the present study, HBZY‑1 cell models treated with high glucose were constructed, and the effects of YAP1 on the proliferation, inflammation, ECM deposition and fibrosis of HBZY‑1 cells were detected. The results showed that YAP1 was highly expressed in HBZY‑1 cells treated with high glucose and that YAP1 silencing decreased cell viability, the levels of inflammatory cytokines, ECM deposition and the degree of fibrosis in cells. Further experiments revealed that NF‑κB/Jumonji domain‑containing protein D3 (JMJD3) signaling pathway inhibitors alleviated the promoting effect of YAP1 overexpression on inflammatory response and ECM deposition in HBZY‑1 cells treated with high glucose. In conclusion, it was demonstrated that YAP1 can promote high glucose‑induced inflammation and ECM deposition by activating the NF‑κB/JMJD3 signaling pathway in GMCs.

View Figures

View References

1	Yuan CM, Nee R, Ceckowski KA, Knight KR and Abbott KC: Diabetic nephropathy as the cause of end-stage kidney disease reported on the medical evidence form CMS2728 at a single center. Clin Kidney J. 10:257–262. 2017.PubMed/NCBI View Article : Google Scholar
2	Duran-Salgado MB and Rubio-Guerra AF: Diabetic nephropathy and inflammation. World J Diabetes. 5:393–398. 2014.PubMed/NCBI View Article : Google Scholar
3	Tessari P: Nitric oxide in the normal kidney and in patients with diabetic nephropathy. J Nephrol. 28:257–268. 2015.PubMed/NCBI View Article : Google Scholar
4	Wada J and Makino H: Inflammation and the pathogenesis of diabetic nephropathy. Clin Sci (Lond). 124:139–152. 2013.PubMed/NCBI View Article : Google Scholar
5	Meza Letelier CE, San Martín Ojeda CA, Ruiz Provoste JJ and Frugone Zaror CJ: Pathophysiology of diabetic nephropathy: A literature review. Medwave. 17(e6839)2017.PubMed/NCBI View Article : Google Scholar : (In Spanish).
6	Xu X, Xiao L, Xiao P, Yang S, Chen G, Liu F, Kanwar YS and Sun L: A glimpse of matrix metalloproteinases in diabetic nephropathy. Curr Med Chem. 21:3244–3260. 2014.PubMed/NCBI View Article : Google Scholar
7	Kwiatkowska E, Domanski L, Bober J, Safranow K, Romanowski M, Pawlik A, Kwiatkowski S and Ciechanowski K: Urinary metalloproteinases-9 and-2 and their inhibitors TIMP-1 and TIMP-2 are markers of early and long-term graft function after renal transplantation. Kidney Blood Press Res. 41:288–297. 2016.PubMed/NCBI View Article : Google Scholar
8	Mazanowska O, Żabińska M, Kościelska-Kasprzak K, Kamińska D, Krajewska M, Banasik M, Madziarska K, Zmonarski SC, Chudoba P, Biecek P, et al: Increased plasma matrix metalloproteinase-2 (MMP-2), tissue inhibitor of proteinase-1 (TIMP-1), TIMP-2, and urine MMP-2 concentrations correlate with proteinuria in renal transplant recipients. Transplant Proc. 46:2636–2639. 2014.PubMed/NCBI View Article : Google Scholar
9	Hu K, Mars WM and Liu Y: Novel actions of tissue-type plasminogen activator in chronic kidney disease. Front Biosci. 13:5174–5186. 2008.PubMed/NCBI View Article : Google Scholar
10	Li FJ, Surolia R, Li H, Wang Z, Liu G, Liu RM, Mirov SB, Athar M, Thannickal VJ and Antony VB: Low-dose cadmium exposure induces peribronchiolar fibrosis through site-specific phosphorylation of vimentin. Am J Physiol Lung Cell Mol Physiol. 313:L80–L91. 2017.PubMed/NCBI View Article : Google Scholar
11	Grampa V, Delous M, Zaidan M, Odye G, Thomas S, Elkhartoufi N, Filhol E, Niel O, Silbermann F, Lebreton C, et al: Novel NEK8 mutations cause severe syndromic renal cystic dysplasia through YAP dysregulation. PLoS Genet. 12(e1005894)2016.PubMed/NCBI View Article : Google Scholar
12	Rinschen MM, Grahammer F, Hoppe AK, Kohli P, Hagmann H, Kretz O, Bertsch S, Höhne M, Göbel H, Bartram MP, et al: YAP-mediated mechanotransduction determines the podocyte's response to damage. Sci Signal. 10(eaaf8165)2017.PubMed/NCBI View Article : Google Scholar
13	Chen Y, Zhao X, Sun J, Su W, Zhang L, Li Y, Liu Y, Zhang L, Lu Y, Shan H and Liang H: YAP1/Twist promotes fibroblast activation and lung fibrosis that conferred by miR-15a loss in IPF. Cell Death Differ. 26:1832–1844. 2019.PubMed/NCBI View Article : Google Scholar
14	Wu Y, Shen L, Liang X, Li S, Ma L, Zheng L, Li T, Yu H, Chan H, Chen C, et al: Helicobacter pylori-induced YAP1 nuclear translocation promotes gastric carcinogenesis by enhancing IL-1β expression. Cancer Med. 8:3965–3980. 2019.PubMed/NCBI View Article : Google Scholar
15	Wang GL, Xia XL, Li XL, He FH and Li JL: Identification and expression analysis of the MSP130-related-2 gene from Hyriopsis cumingii. Genet Mol Res. 14:4903–4913. 2015.PubMed/NCBI View Article : Google Scholar
16	Mulder S, Hamidi H, Kretzler M and Ju W: An integrative systems biology approach for precision medicine in diabetic kidney disease. Diabetes Obes Metab. 20 (Suppl 3):S6–S13. 2018.PubMed/NCBI View Article : Google Scholar
17	Choi SY, Bae H, Jeong SH, Park I, Cho H, Hong SP, Lee DH, Lee CK, Park JS, Suh SH, et al: YAP/TAZ direct commitment and maturation of lymph node fibroblastic reticular cells. Nat Commun. 11(519)2020.PubMed/NCBI View Article : Google Scholar
18	Ma R, Ren JM, Li P, Zhou YJ, Zhou MK, Hu Z and Xiao XY: Activated YAP causes renal damage of type 2 diabetic nephropathy. Eur Rev Med Pharmacol Sci. 23:755–763. 2019.PubMed/NCBI View Article : Google Scholar
19	Han N, Tian W, Yu N and Yu L: YAP1 is required for the angiogenesis in retinal microvascular endothelial cells via the inhibition of MALAT1-mediated miR-200b-3p in high glucose-induced diabetic retinopathy. J Cell Physiol. 235:1309–1320. 2020.PubMed/NCBI View Article : Google Scholar
20	Park MJ, Kim DI, Lim SK, Choi JH, Han HJ, Yoon KC and Park SH: High glucose-induced O-GlcNAcylated carbohydrate response element-binding protein (ChREBP) mediates mesangial cell lipogenesis and fibrosis: The possible role in the development of diabetic nephropathy. J Biol Chem. 289:13519–13530. 2014.PubMed/NCBI View Article : Google Scholar
21	Wang J, Yang Q, Nie Y, Guo H, Zhang F, Zhou X and Yin X: Tetrahydrobiopterin contributes to the proliferation of mesangial cells and accumulation of extracellular matrix in early-stage diabetic nephropathy. J Pharm Pharmacol. 69:182–190. 2017.PubMed/NCBI View Article : Google Scholar
22	Sakaki H, Okada M, Kuramoto K, Takeda H, Watarai H, Suzuki S, Seino S, Seino M, Ohta T, Nagase S, et al: GSKJ4, a selective jumonji H3K27 demethylase inhibitor, effectively targets ovarian cancer stem cells. Anticancer Res. 35:6607–6614. 2015.PubMed/NCBI
23	Tokunaga R, Sakamoto Y, Nakagawa S, Miyake K, Izumi D, Kosumi K, Taki K, Higashi T, Imamura Y, Ishimoto T, et al: The prognostic significance of histone lysine demethylase JMJD3/KDM6B in colorectal cancer. Ann Surg Oncol. 23:678–685. 2016.PubMed/NCBI View Article : Google Scholar
24	Chen Y, Liu Z, Pan T, Chen E, Mao E, Chen Y, Tan R, Wang X, Tian R, Liu J and Qu H: JMJD3 is involved in neutrophil membrane proteinase 3 overexpression during the hyperinflammatory response in early sepsis. Int Immunopharmacol. 59:40–46. 2018.PubMed/NCBI View Article : Google Scholar
25	Jia W, Wu W, Yang D, Xiao C, Su Z, Huang Z, Li Z, Qin M, Huang M, Liu S, et al: Histone demethylase JMJD3 regulates fibroblast-like synoviocyte-mediated proliferation and joint destruction in rheumatoid arthritis. FASEB J. 32:4031–4042. 2018.PubMed/NCBI View Article : Google Scholar
26	Yu S, Chen X, Xiu M, He F, Xing J, Min D and Guo F: The regulation of Jmjd3 upon the expression of NF-κB downstream inflammatory genes in LPS activated vascular endothelial cells. Biochem Biophys Res Commun. 485:62–68. 2017.PubMed/NCBI View Article : Google Scholar
27	Lai J, Ge M, Shen S, Yang L, Jin T, Cao D, Xu H, Zheng X, Qiu S, Wang K, et al: Activation of NFKB-JMJD3 signaling promotes bladder fibrosis via boosting bladder smooth muscle cell proliferation and collagen accumulation. Biochim Biophys Acta Mol Basis Dis. 1865:2403–2410. 2019.PubMed/NCBI View Article : Google Scholar
28	Ye S, Lawlor MA, Rivera-Reyes A, Egolf S, Chor S, Pak K, Ciotti GE, Lee AC, Marino GE, Shah J, et al: YAP1-mediated suppression of USP31 enhances NFκB activity to promote sarcomagenesis. Cancer Res. 78:2705–2720. 2018.PubMed/NCBI View Article : Google Scholar